glp 1 amplifier quicksilver GLP-1 - Scientific GLP-1 Amplifier
Description
The CV safety of a lower dose of liraglutide (1.8 mg, Victoza, Novo Nordisk) in people with T2D was established in the Liraglutide Effect and Action in Diabetes: Evaluation of CV Outcome Results (LEADER) study, showing a 13% reduction in major CV events over an average of 3.8 years [44]
doi: 10.1002/jnr.23181 [DOI] [PubMed] [Google Scholar] 174
Initial results from a randomized controlled trial indicated that it reduced weight and improved diabetic control
Jeffrey Egler
Health conditions such as diabetes and hypoglycemia can significantly affect your blood sugar levels
